0001879971-23-000002.txt : 20231002
0001879971-23-000002.hdr.sgml : 20231002
20231002170026
ACCESSION NUMBER: 0001879971-23-000002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230901
FILED AS OF DATE: 20231002
DATE AS OF CHANGE: 20231002
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Seabaugh Ramona
CENTRAL INDEX KEY: 0001879971
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36533
FILM NUMBER: 231300486
MAIL ADDRESS:
STREET 1: C/O MEDAVAIL TECHNOLOGIES INC.
STREET 2: 6665 MILLCREEK DR, UNIT 1
CITY: MISSISSAUGA
STATE: A6
ZIP: L5N 5M4
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MedAvail Holdings, Inc.
CENTRAL INDEX KEY: 0001402479
STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
IRS NUMBER: 900772394
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4720 E COTTON GIN LOOP
STREET 2: SUITE 220
CITY: PHOENIX
STATE: AZ
ZIP: 85040
BUSINESS PHONE: 1.877.830.0826
MAIL ADDRESS:
STREET 1: 4720 E COTTON GIN LOOP
STREET 2: SUITE 220
CITY: PHOENIX
STATE: AZ
ZIP: 85040
FORMER COMPANY:
FORMER CONFORMED NAME: MYOS RENS TECHNOLOGY INC.
DATE OF NAME CHANGE: 20160322
FORMER COMPANY:
FORMER CONFORMED NAME: MYOS Corp
DATE OF NAME CHANGE: 20120521
FORMER COMPANY:
FORMER CONFORMED NAME: Atlas Therapeutics Corp
DATE OF NAME CHANGE: 20100719
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0508
4
2023-09-01
0
0001402479
MedAvail Holdings, Inc.
MDVL
0001879971
Seabaugh Ramona
C/O MEDAVAIL TECHNOLOGIES INC.
4720 E. COTTON GIN LOOP, SUITE 220
PHOENIX
AZ
85040
0
1
0
0
Chief Financial Officer
1
Common Stock
2023-09-01
4
M
0
680
0
A
1525
D
Common Stock
2023-09-28
4
S
0
303
5.6971
D
1222
D
Restricted Stock Units
2023-09-01
4
M
0
680
0
D
2031-09-20
Common Stock
680
679
D
On July 31, 2023, the Issuer effected a 1-for-50 reverse stock split of the issued and outstanding shares of its common stock. Upon effectiveness of the reverse stock split, every 50 shares of common stock were automatically converted into one share of common stock. The securities reported on this Form 4 have been adjusted to reflect the reverse stock split.
This amount includes 480 net shares acquired by the reporting person upon the vesting of 680 restricted stock units on September 1, 2022. 200 shares were withheld by the Issuer in payment of the reporting person's tax liability. The disposition of the restricted stock units and the acquisition of the shares of common stock that occurred upon vesting of the restricted stock units were not previously reported by the reporting person.
The reporting person sold these shares pursuant to an arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1 solely to cover tax withholding obligations in connection with the vesting of restricted stock units.
These shares were sold in multiple transactions at prices ranging from $5.69 to $5.98, inclusive. The prices reported in this Form 4 reflect the weighted-average sale price. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. The amount reflected has been rounded to four decimal points.
Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
On September 20, 2021, the reporting person was granted 2,039 restricted stock units under the Issuer's 2020 Equity Incentive Plan, with one third (1/3rd) of the units scheduled to vest on each of the one (1), two (2), and three (3) year anniversaries of September 1, 2021, the vesting commencement date.
This amount excludes 680 shares disposed of by the reporting person upon the vesting of restricted stock units on September 1, 2022. The disposition of the restricted stock units and the acquisition of the shares of common stock that occurred upon vesting of the restricted stock units were not previously reported by the reporting person.
/s/Ramona Seabaugh
2023-10-02